On Monday afternoon, the stock market responded to news that an experimental vaccine had successfully produced an antibody response in the first six individuals to receive it as part of a phase 1 clinical trial.  One day later, the market dropped precipitously in its closing moments on news that it was too early for this particular vaccine candidate to be declared successful.  It was a whip-saw reaction that feels particularly … Read More